A Study to Evaluate the Predictive Role of Tumour Markers in Patients with Advanced-stage Non Small Cell Lung Cancer (NSCLC) Treated with Erlotinib

Trial Profile

A Study to Evaluate the Predictive Role of Tumour Markers in Patients with Advanced-stage Non Small Cell Lung Cancer (NSCLC) Treated with Erlotinib

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 May 2016 Results published in the Anticancer Research
    • 08 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top